Olema Logo® - RGB.png
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
25 nov. 2024 17h30 HE | Olema Oncology
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Logo® - RGB.png
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
12 nov. 2024 16h01 HE | Olema Oncology
Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on...
Olema Logo® - RGB.png
Olema Oncology to Participate in Upcoming Investor Conferences
06 nov. 2024 07h01 HE | Olema Oncology
SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
06 août 2024 16h02 HE | Olema Oncology
Presented promising interim clinical results from the ongoing study of palazestrant in combination with ribociclib at the 2024 ESMO Breast Cancer Congress. Updated results expected to be presented at...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology to Participate in Upcoming Investor Conferences in June
28 mai 2024 07h03 HE | Olema Oncology
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
15 mai 2024 07h01 HE | Olema Oncology
Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
08 mai 2024 16h02 HE | Olema Oncology
Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination with each of ribociclib and palbociclibNew clinical data from palazestrant-ribociclib combination study to...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
08 mai 2024 07h02 HE | Olema Oncology
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
11 mars 2024 16h03 HE | Olema Oncology
Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4 2023 Initiated OPERA-01 pivotal Phase 3...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07 nov. 2023 16h02 HE | Olema Oncology
OPERA-01 pivotal Phase 3 monotherapy clinical trial on track, with clinical site activation ongoing and first patient expected to be enrolled in fourth quarterNew clinical data for palazestrant...